Top section
Top section
◆ Have capital markets comprehended the heatwave? ◆ Which SSA issuers need to get it done this autumn ◆ Halcyon days for MTN, M&A and ECM bankers
Investors pay little heed to alarming worsening of climate
New $75m partnership to develop treatment for lymphoma was “catalyst for investors”
More articles
More articles
More articles
-
Chinese technology company Duiba Group reaffirmed its IPO hopes on Monday, once again filing a prospectus with the Hong Kong stock exchange. -
The UK’s new Brexit Bond Management Office is still preparing to issue its first notes, originally scheduled for last Friday. The Brexit-themed Gilts are sized at £36.4bn, equivalent to £350m a week over their two year maturity.
-
Pharmaceutical giant AstraZeneca has entered into a collaboration agreement with Japanese pharmaceutical company Daiichi Sankyo to develop a new antibody-drug conjugate which it is hoped will revolutionise cancer treatment. The deal is being funded through an equity capital raise.
-
Talos Capital has sold a €191.4m stake in Aena SME, the Spanish airport operator, capping off the biggest week for equity block trades in Europe this year.
-
Centerbridge Partners has sold a €119.2m chunk of its stake in Banca Farmafactoring, the Italian factoring company that specialises in payments owed by public institutions to the healthcare sector, after the stock has rebounded since October.
-
Indian real estate major DLF bagged Rp31.7bn ($458.7m) this week after wrapping up its qualified institutional placement (QIP), with investors winning a near 5% discount to the floor price.
Sub-sections
shared comment list
